Global Depression Drug Market to Increase to $16.8 billion by 2020

Deerfield Beach, FL -- (SBWire) -- 10/10/2017 --According to the report, the global depression drug market was valued at USD 14.51 billion in 2014 and is expected to generate revenue of USD 16.8 billion by end of 2020, growing at a CAGR of 2.50% between 2015 and 2020. Zion Market Research has published a new report titled "Depression Drug (Benzodiazepines, SNRIs, TCAs, TeCAs, Atypical Antipsychotics, Monoamine Oxidase Inhibitors and Others) Market: Global Industry Perspective, Comprehensive Analysis, and Forecast, 2014 – 2020"

Depression is an illness that leads to continual loss of interest and feeling of sadness. Clinical depression or depressive disorder affects the way someone feels, thinks and behaves and can cause several physical and emotional problems. The age group with the utmost rates of depression is below 20 years, with puberty being the usual age of beginning for depression. Depression is a very widespread illness, affecting about 10% to 15% of men and 10% to 25% of women. Although depression affects individuals of all ages, around twice as many women as men are treated with a clinical depressive.

Request For Free Sample Report: https://goo.gl/76aZgm

A major driver of the global depression drug market is the escalating prevalence of anxiety and depression disorders. Some of the key reasons driving depression drug market are growing geriatric population and rising effectiveness and declining side effects of drugs in numerous classes. However, drug resistant-mental disorders are likely to challenge the growth of the depression drug market. Regardless of this decline in sales high global prevalence of depression which is a major reason of disability and small market penetration in a few areas, offers several opportunities.

The different types of depression also have different symptoms, including major or clinical depressive disorder, postpartum depression, dysthymic disorder, psychotic depression and seasonal affective disorder. Depending upon class global depression drug market is segmented as anticonvulsants, serotonin-norepinephrine reuptake inhibitors, selective serotonin reuptake inhibitors (SSRIs), beta-blockers, benzodiazepines, tetracyclic antidepressants (TeCAs) and monoamine oxidase inhibitors (MAOIs) among others. SNRIs emerged as a potential segment in 2014 and acquired more than 32% of the overall market share. However, it is estimated that this segment may exhibit a decline in growth in the near future.

Know more before buying this report: https://goo.gl/BZCM2T

North America emerged as the major regional market for the global depression in 2014. This dominance was mainly because of the presence of large population infected with numerous kinds of depression and anxiety disorders. Currently, U.S. is saturated as a variety of antidepressant drugs are available on prescription for the similar symptom. Around 9% of the U.S. population suffers from depression. Globally less than 50% of depressed patients take treatment for depression. Every year an estimated around 1.5 million people or 1 in 20 Canadians, report several forms of anxiety disorder or depression. In fact, about 1 in 10 women is expected to suffer postpartum depression in the month subsequent childbirth. In Asia Pacific, strong economic growth in economies such as China, Japan, and Australia would contribute to the growth of the depression drug market.

Browse the full report at: http://www.marketresearchstore.com/report/depression-drug-market-z53043

Different industry participants in this market will benefit from the development of herbal remedies along with the improvements in the distribution network in promising economies. The key players operating in this market are Forest Laboratories, AstraZeneca, GlaxoSmithKline, Abbott Laboratories, H. Lundbeck, Merck & Co., and Eli Lilly and Company.